Vol 66, No 1 (2016)
Oncological debates
Published online: 2016-04-07
Page views
684
Article views/downloads
4181
Progression-free survival as a reliable criterion for assessment of the value of systemic anticancer therapy
Nowotwory. Journal of Oncology 2016;66(1):68-69.
Abstract
Hazards related with the choice of progression-free survival as a criterion for assessment of the value of systemic anticancer therapy are presented in this study. The arguments for overall survival as reliable end-point in clinical trials in oncology are discussed.